Making A Market In Women’s Health: Endometriosis, Fibroids Emerge As Rx Targets
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Candidates like AbbVie’s elagolix and Actavis’ Esmya promise oral therapy without the drawbacks of the artificial menopause induced by available hormone suppression therapy – and may pave the way for newer approaches while expanding the market.